Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLCO1B1 | Q9Y6L6 | 8/20 | 0.63 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.63 |
| ▸ | LPAR1 | Q92633 | 7/20 | 0.48 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.47 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.47 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21097257 | 1.00 | SLCO1B1 (0.63) | SLCO1B1ABCB11LPAR1ABCC3ABCC4 | |
| SCHEMBL22436303 | 0.92 | SLCO1B1 (0.64) | SLCO1B1ABCB11LPAR1ABCC3ABCC4 | |
| SCHEMBL21994144 | 0.92 | SLCO1B1 (0.64) | SLCO1B1ABCB11LPAR1ABCC3ABCC4 | |
| SCHEMBL22436301 | 0.92 | SLCO1B1 (0.64) | SLCO1B1ABCB11LPAR1ABCC3ABCC4 | |
| SCHEMBL21057881 | 0.92 | SLCO1B1 (0.64) | SLCO1B1ABCB11LPAR1ABCC3ABCC4 | |
| SCHEMBL21097275 | 0.90 | SLCO1B1 (0.62) | SLCO1B1ABCB11LPAR1ABCC3ABCC4 | |
| SCHEMBL21097274 | 0.90 | SLCO1B1 (0.62) | SLCO1B1ABCB11LPAR1ABCC3ABCC4 | |
| SCHEMBL21097158 | 0.90 | SLCO1B1 (0.64) | SLCO1B1ABCB11LPAR1ABCC3ABCC4 | |
| SCHEMBL21097163 | 0.90 | SLCO1B1 (0.64) | SLCO1B1ABCB11LPAR1ABCC3ABCC4 | |
| SCHEMBL21097155 | 0.90 | SLCO1B1 (0.62) | SLCO1B1ABCB11LPAR1ABCC3ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662172-B2 | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190185446-A1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185446-A1 | TRIAZOLE N-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | SLCO1B1 1395/4885ABCB11 1766/4885LPAR1 2/4885 |
| US-10662172-B2 | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | LPAR3, LPAR1, LPAR2 | SLCO1B1 1395/4885ABCB11 1766/4885LPAR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.